FDA sets stepped Foundayo dosing from 0.8 mg to 17.2 mg
Foundayo's label builds in at least a month at every dose level, so the oral GLP-1 pill cannot be ramped up quickly.
The FDA approved Foundayo (orforglipron) on April 1, 2026, as a once-daily tablet for adults with obesity, or with overweight plus at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity [1]. The label's dosing schedule starts at 0.8 mg and climbs in steps over several months to a maximum of 17.2 mg [1].
How the schedule works
Treatment begins at 0.8 mg once daily. The dose increases to 2.5 mg after at least 30 days, then to 5.5 mg after another 30 days. Further increases to 9 mg, 14.5 mg, or 17.2 mg are permitted after at least 30 days at each level, based on treatment response and tolerability [1]. Reaching the top dose therefore takes a minimum of about five months.
The approval announcement does not explain why the schedule is stepped. The side effects listed for Foundayo include nausea, constipation, diarrhea, vomiting, dyspepsia, stomach pain, headache, abdominal extension, fatigue, burping, gastroesophageal reflux disease, gas, and hair loss [1].
The evidence and the warnings
Two randomized, double-blind, placebo-controlled trials in adults with obesity, or with overweight and one or more weight-related conditions, supported the approval. In those trials, 72 weeks of Foundayo with a reduced-calorie diet and increased physical activity produced a statistically significant and clinically meaningful reduction in body weight compared with placebo [1]. The agency did not include the average percentage of weight lost in its announcement.
Foundayo's label carries warnings and precautions for pancreatitis, severe gastrointestinal reactions, acute kidney injury due to volume depletion, hypoglycemia, hypersensitivity, diabetic retinopathy in patients with type 2 diabetes, acute gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation. It also carries a boxed warning for thyroid C-cell tumors and should not be used in people with a personal or family history of medullary thyroid cancer or with Multiple Endocrine Neoplasia syndrome type 2. It should not be combined with another GLP-1 receptor agonist [1].
The FDA approved Foundayo 50 days after the application was filed, 294 days before its PDUFA date of January 20, 2027. It was the first new molecular entity approved under the agency's Commissioner's National Priority Voucher pilot, and the fastest approval of a new molecular entity since 2002 [1]. Acting CDER director Tracy Beth Høeg described it as "a GLP-1 receptor partial agonist pill which does not need to be taken on an empty stomach" [1].
Outside the US
The UK Medicines and Healthcare products Regulatory Agency authorized Foundayo on August 10, 2026, for weight management and for glycemic control in type 2 diabetes that is not adequately controlled. Dosing there also begins at 0.8 mg and escalates through five further steps to 17.2 mg, with a minimum of one month at each level. Lilly began UK supply on August 24 through private prescription only, with private pricing indicated at £100 to £120 per month; the medicine is not available on the NHS [2].
Lilly submitted orforglipron to the FDA for type 2 diabetes during the second quarter of 2026, and the FDA approved it for obesity in April 2026 [2].
Why it matters for patients
Foundayo is a tablet rather than an injection, and the labeling allows it to be taken without food or water restrictions [1][2]. That differs from oral semaglutide (Rybelsus), which requires a fasting window [2]. The stepped schedule is a built-in delay: a patient starting at 0.8 mg spends at least a month at each of the first two steps before reaching 5.5 mg, and at least about five months before any higher dose is considered [1]. The label lists a broad set of gastrointestinal and other side effects, plus a boxed warning for thyroid C-cell tumors [1]. Foundayo cannot be taken with another GLP-1 receptor agonist, so people already using semaglutide or tirzepatide would need to switch rather than add it [1]. US pricing and insurance coverage for Foundayo have not been reported [1][2].
What happens next
The FDA will host a public meeting on June 4, rescheduled from June 12, on the CNPV pilot program, with written comments accepted through June 29, 2026 [1]. In the UK, the National Institute for Health and Care Excellence has not set a date for a second committee meeting on orforglipron, and its appraisal listing carries an expected publication date of November 18, 2026 [2]. No decision date has been reported for Lilly's US application covering type 2 diabetes [2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.